ReviewAdvances in experimental medicine and biology2026
Recent Characterization of Key Proteins to Combat Tuberculosis.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent large-scale proteogenomic analyses of Mycobacterium tuberculosis (Mtb) have significantly deepened our understanding of its proteome by delineating two major classes of proteins: canonical proteins and microproteins. Canonical proteins, encoded by well-annotated open reading frames (ORFs), perform essential functions in fundamental cellular processes, including DNA replication, metabolism, virulence regulation, and adaptation to stress. Concurrently, growing attention has been directed toward microproteins, small polypeptides translated from previously unannotated small ORFs, which have increasingly been recognized as key modulators of bacterial growth, persistence, and antibiotic response. Microproteins commonly exhibit structural characteristics such as intrinsically disordered regions, signal peptides, and transmembrane domains, enabling their participation in diverse cellular pathways, including membrane dynamics, signal transduction, and transcriptional regulation. These insights highlight the remarkable regulatory complexity and proteomic versatility that underpin Mtb's ability to adapt to host-imposed stress conditions. A significant advancement is the emerging understanding of conserved hypothetical proteins (CHPs), a long-overlooked group previously considered functionally ambiguous. Recent structural and functional characterizations have uncovered critical roles for many CHPs in vital biological processes, such as cell wall biosynthesis, DNA maintenance, metabolic control, and environmental stress responses. Notably, several newly characterized members of both microproteins and CHPs have surfaced as promising vaccine candidates owing to their strong immunogenicity and as attractive drug targets due to their essentiality and amenability to structural studies. Additionally, some exhibit potential as diagnostic biomarkers based on their infection-specific expression and recognition by the host immune system. Collectively, this expanded repertoire, especially the newly characterized proteins, significantly enhances our understanding of Mtb pathogenesis, adaptability, and persistence.
Indexed as
Identifiers
41207944What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.